BIOTECH PARK COMPANY: LIFECARE INNOVATIONS LEADING ANTI-MALARIAL DRUG DEVELOPMENT IN INDIA-CANADA CONSORTIUM


The India - Canada International Malaria Consortium met in MaRS last week to develop a number of drug targets for new chemical classes of drugs that are able to overcome drug resistance for malaria.

Lifecare Innovations, with its vast experience in novel drug delivery systems, is leading the drug formulation efforts for a single dose and sustained release nano formulation at Laboratory for Translational Research in Nanomedicine, Biotech Park, Janakipuram, Lucknow, India.
Malaria is present in more than 100 countries. About 3.2 billion people are at risk of malaria. Concerns of widespread resistance to treatment are increasing as parasite resistance to anti malarial has been documented in three of the five malaria species known to affect humans. As the threat of anti malarial drug resistance grows, there is an urgent need for novel classes of anti malarials both in the developing and developed world.
The India-Canada International Malaria Consortium is a joint research and development program between the Indian organizations [International Center for Genetic Engineering & Biotechnology/ICGEB (Principal Investigator: Dr. Asif Mohmmed), Birla Institute of Tech & Sci-Pilani and Lifecare Innovations Pvt Ltd ( Industry : Dr. Jitendra N. Verma) ] and  Ontario organizations [University Health Network (Canadian Principal Investigator: Dr. Lakshmi P. Kotra), Therapure Biopharma, Nucro-Technics Inc. and CIDAVA Innovations Inc.]
With funding from Government of India, Government of Canada and Government of Ontario, this consortium has been working on a number of drug targets to develop new chemical classes of drugs that are able to overcome drug resistance to provide improved global solutions for malaria therapy.